FOXP3 and asthma: The expression of Foxp3 [28.1% (4.9–61.0%) vs 36.4% (13.7–52.9%)], CD25 [14.3% (0–28.8%) vs 14.9% (7.9–28.9%)] or IL-4 [16.9% (3.5–37.3%) vs 10.7% (0–34.0%)] in CD4+TGF-β+ cells did not differ significantly between asthma and control groups.